Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHA:600381)
4.770
-0.080 (-1.65%)
May 21, 2026, 3:00 PM CST
SHA:600381 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 162.79 | 166.37 | 207.22 | 172.26 | 168.69 | 164.94 |
Short-Term Investments | - | - | - | - | 1.63 | - |
Trading Asset Securities | 0.75 | 0.74 | 0.74 | 0.67 | 0.66 | 34.65 |
Cash & Short-Term Investments | 163.54 | 167.11 | 207.96 | 172.93 | 170.98 | 199.59 |
Cash Growth | 29.00% | -19.64% | 20.26% | 1.14% | -14.33% | -6.08% |
Accounts Receivable | 68.11 | 51.79 | 70.99 | 62.95 | 55.37 | 108.13 |
Other Receivables | 4.44 | 2.53 | 0.44 | 6.64 | 10.26 | 18.93 |
Receivables | 72.55 | 54.32 | 71.42 | 69.59 | 65.63 | 127.06 |
Inventory | 143.32 | 159.29 | 174 | 297.11 | 333.5 | 394.5 |
Other Current Assets | 252.57 | 270.58 | 164.77 | 209.61 | 245.9 | 273.31 |
Total Current Assets | 631.97 | 651.3 | 618.15 | 749.24 | 816 | 994.46 |
Property, Plant & Equipment | 238.06 | 242.07 | 262.15 | 296.42 | 281.18 | 296.92 |
Long-Term Investments | 41.98 | 41.98 | 51.89 | 89 | 228.97 | 270.96 |
Other Intangible Assets | 58.96 | 59.3 | 74.29 | 83.25 | 84.68 | 145.78 |
Long-Term Deferred Tax Assets | 31.31 | 31.33 | 38.62 | 31.34 | 30.83 | 23 |
Long-Term Deferred Charges | 5.86 | 6.39 | 6.63 | 8.08 | 2.33 | 3.13 |
Other Long-Term Assets | 11.99 | 12.11 | 112.56 | 101.99 | 115.24 | 113.87 |
Total Assets | 1,020 | 1,044 | 1,164 | 1,359 | 1,559 | 1,848 |
Accounts Payable | 6.75 | 4.13 | 9.09 | 6.77 | 2.67 | 3.74 |
Accrued Expenses | 1.22 | 3.02 | 16.35 | 17.2 | 9.01 | 7.21 |
Current Portion of Long-Term Debt | 2.24 | 2.56 | - | - | - | - |
Current Portion of Leases | - | - | 8.82 | 8.83 | 1.95 | 0.55 |
Current Income Taxes Payable | 0.65 | 5.95 | 2.07 | 2.17 | - | - |
Current Unearned Revenue | 14.95 | 15.48 | 83.66 | 40.44 | 2.31 | 9.63 |
Other Current Liabilities | 9.97 | 12.97 | 4.55 | 5.73 | 5.79 | 3.59 |
Total Current Liabilities | 35.78 | 44.12 | 124.55 | 81.14 | 21.73 | 24.7 |
Long-Term Leases | 0.37 | 0.41 | 2.98 | 9.83 | 2.95 | 0.58 |
Long-Term Unearned Revenue | 0.32 | 0.34 | 0.5 | 1.01 | 1.63 | 2.36 |
Long-Term Deferred Tax Liabilities | - | - | - | 0 | - | - |
Total Liabilities | 36.47 | 44.87 | 128.02 | 91.99 | 26.3 | 27.64 |
Common Stock | 587.06 | 587.06 | 587.06 | 587.06 | 587.06 | 587.06 |
Additional Paid-In Capital | 237.37 | 237.37 | 237.37 | 237.37 | 237.37 | 237.37 |
Retained Earnings | 188.27 | 204.54 | 241.86 | 440.63 | 708.5 | 996.04 |
Treasury Stock | -33.75 | -33.75 | -33.75 | - | - | - |
Total Common Equity | 978.96 | 995.23 | 1,033 | 1,265 | 1,533 | 1,820 |
Minority Interest | 4.71 | 4.37 | 3.71 | 2.25 | -0 | - |
Shareholders' Equity | 983.66 | 999.61 | 1,036 | 1,267 | 1,533 | 1,820 |
Total Liabilities & Equity | 1,020 | 1,044 | 1,164 | 1,359 | 1,559 | 1,848 |
Total Debt | 2.61 | 2.97 | 11.8 | 18.66 | 4.9 | 1.13 |
Net Cash (Debt) | 160.93 | 164.15 | 196.16 | 154.27 | 166.09 | 198.46 |
Net Cash Growth | 38.59% | -16.32% | 27.15% | -7.11% | -16.31% | -6.61% |
Net Cash Per Share | 0.30 | 0.31 | 0.34 | 0.26 | 0.28 | 0.34 |
Filing Date Shares Outstanding | 553.6 | 433.57 | 572.36 | 587.06 | 587.06 | 587.06 |
Total Common Shares Outstanding | 553.6 | 433.57 | 572.36 | 587.06 | 587.06 | 587.06 |
Working Capital | 596.19 | 607.18 | 493.61 | 668.09 | 794.28 | 969.75 |
Book Value Per Share | 1.77 | 2.30 | 1.80 | 2.15 | 2.61 | 3.10 |
Tangible Book Value | 919.99 | 935.93 | 958.26 | 1,182 | 1,448 | 1,675 |
Tangible Book Value Per Share | 1.66 | 2.16 | 1.67 | 2.01 | 2.47 | 2.85 |
Buildings | - | - | 306.66 | 319.75 | 298.95 | 301.11 |
Machinery | - | - | 110.16 | 107.22 | 106.11 | 105.92 |
Construction In Progress | - | - | - | - | 1.28 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.